Victory Capital Management Inc. Purchases 11,385 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Victory Capital Management Inc. lifted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 59.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,537 shares of the company’s stock after purchasing an additional 11,385 shares during the period. Victory Capital Management Inc.’s holdings in Dyne Therapeutics were worth $1,097,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares during the period. American International Group Inc. raised its holdings in Dyne Therapeutics by 31.8% in the 1st quarter. American International Group Inc. now owns 29,138 shares of the company’s stock worth $827,000 after purchasing an additional 7,027 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Dyne Therapeutics by 8,284.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares during the period. California State Teachers Retirement System boosted its stake in shares of Dyne Therapeutics by 29.9% during the 1st quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock valued at $1,271,000 after purchasing an additional 10,317 shares in the last quarter. Finally, Artal Group S.A. increased its position in shares of Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after buying an additional 300,000 shares during the period. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Performance

NASDAQ:DYN opened at $29.23 on Wednesday. The firm has a market cap of $2.97 billion, a P/E ratio of -8.16 and a beta of 1.10. Dyne Therapeutics, Inc. has a fifty-two week low of $10.12 and a fifty-two week high of $47.45. The firm has a 50-day simple moving average of $32.06 and a two-hundred day simple moving average of $35.40.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Stifel Nicolaus upped their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Finally, Guggenheim upped their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.82.

Insiders Place Their Bets

In other news, Director Jason P. Rhodes sold 782 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares of the company’s stock, valued at $528,342.20. This represents a 4.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 176,257 shares of company stock valued at $6,193,718. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.